Total revenue for Q1 2026 was $216.2 million, an increase of 78.8% compared to $120.9 million in Q1 2025. Molecular profiling services revenue reached $210.8 million, up 84.8% year-over-year. Net loss for the quarter was $0.5 million, a significant improvement from the $102.6 million loss in Q1 2025. Adjusted EBITDA was $26.2 million, compared to $(36.2) million in the prior year period. Clinical case volume increased to 52,800 cases in Q1 2026 from 45,900 in Q1 2025.